retatrutide approval status 2025 fda ema New Drug Approvals: Key and approvals and Emerging Trends When will Retatrutide be available
Description
Deane AM, Nguyen NQ, Stevens JE, et al
Does GLP-1 cause diarrhea
But the clinical trial data supports extending any step by 2 to 4 additional weeks if side effects remain problematic
This reinforces the point that retatrutide dosing in trials is about consistency and safety, not improvisation
Patient safety is central to our approach
